JO3749B1 - تركيبات إنسولين سريعة المفعول - Google Patents

تركيبات إنسولين سريعة المفعول

Info

Publication number
JO3749B1
JO3749B1 JOP/2016/0183A JOP20160183A JO3749B1 JO 3749 B1 JO3749 B1 JO 3749B1 JO P20160183 A JOP20160183 A JO P20160183A JO 3749 B1 JO3749 B1 JO 3749B1
Authority
JO
Jordan
Prior art keywords
rapid
acting insulin
insulin compositions
insulin analog
insulin
Prior art date
Application number
JOP/2016/0183A
Other languages
English (en)
Inventor
Edward CHRISTE Michael
Kumar Sarin Virender
D Paavola Chad
Patrick Akers Michael
Andrew HARDY Thomas
Majumdar Ranajoy
A Nguyen Chi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57003563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3749(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3749B1 publication Critical patent/JO3749B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

يتعلق الاختراع الحالي بتركيبة صيدلية لإنسولين البشري أو نظير إنسولين تتضمن سيترات، تريبروستينيل وعوامل تثبيت، يكون لها نشاط حركي دوائي و/ أو دوائي ديناميكي أسرع من صيغ تجارية لمنتجات نظير إنسولين متاحة وتكون مستقرة للاستخدام التجاري.
JOP/2016/0183A 2015-08-27 2016-08-14 تركيبات إنسولين سريعة المفعول JO3749B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562210469P 2015-08-27 2015-08-27

Publications (1)

Publication Number Publication Date
JO3749B1 true JO3749B1 (ar) 2021-01-31

Family

ID=57003563

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0183A JO3749B1 (ar) 2015-08-27 2016-08-14 تركيبات إنسولين سريعة المفعول

Country Status (39)

Country Link
US (3) US9901623B2 (ar)
EP (2) EP3340966B1 (ar)
JP (2) JP6359780B2 (ar)
KR (1) KR102018998B1 (ar)
CN (1) CN107920992B (ar)
AR (1) AR105712A1 (ar)
AU (1) AU2016310475B2 (ar)
BR (1) BR112018001755A2 (ar)
CA (1) CA2994427C (ar)
CL (1) CL2018000503A1 (ar)
CO (1) CO2018002026A2 (ar)
CR (1) CR20180118A (ar)
DK (1) DK3340966T3 (ar)
DO (1) DOP2018000059A (ar)
EA (1) EA033396B1 (ar)
EC (1) ECSP18014922A (ar)
ES (1) ES2928664T3 (ar)
FI (1) FI3340966T3 (ar)
HR (1) HRP20221367T1 (ar)
HU (1) HUE060626T2 (ar)
IL (1) IL256939B (ar)
JO (1) JO3749B1 (ar)
LT (1) LT3340966T (ar)
MA (1) MA42701B1 (ar)
MD (1) MD3340966T2 (ar)
MX (1) MX2018002482A (ar)
MY (1) MY195781A (ar)
NZ (1) NZ739338A (ar)
PE (1) PE20180782A1 (ar)
PH (1) PH12018500422A1 (ar)
PL (1) PL3340966T3 (ar)
PT (1) PT3340966T (ar)
RS (1) RS63731B1 (ar)
SV (1) SV2018005643A (ar)
TN (1) TN2018000056A1 (ar)
TW (1) TWI614025B (ar)
UA (1) UA120142C2 (ar)
WO (1) WO2017034956A1 (ar)
ZA (1) ZA201800511B (ar)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9700599B2 (en) 2012-11-13 2017-07-11 Adocia Rapid-acting insulin formulation comprising a substituted anionic compound
TW201630622A (zh) * 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
ES2912162T3 (es) 2017-06-01 2022-05-24 Lilly Co Eli Composiciones de insulina de acción rápida
WO2019050749A1 (en) * 2017-09-08 2019-03-14 Eli Lilly And Company PHARMACEUTICAL COMBINATIONS COMPRISING INSULIN AND AT LEAST ONE AGENT SELECTED AMONG MELOXICAM, BROMFENAC SODIUM, ACETYLSALICYLIC ACID, SALICYLIC ACID AND PARACETAMOL
US20210093775A1 (en) * 2018-04-04 2021-04-01 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
CA3094308A1 (en) * 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
IL277721B2 (en) * 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump for administering an insulin compound
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083984A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
US20220047535A1 (en) * 2018-09-18 2022-02-17 Eli Lilly And Company Novel Treprostinil Salt
EP3996679B1 (en) * 2019-07-12 2023-09-06 Novo Nordisk A/S High concentration insulin formulation
TW202214292A (zh) * 2020-06-30 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 速效胰島素組成物及其醫藥用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740953A1 (de) 1977-09-12 1979-03-22 Thera Ges Fuer Patente Verwendung von prostaglandinen zur senkung des blutzuckerspiegels
DE3064888D1 (en) 1979-04-30 1983-10-27 Hoechst Ag Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
ZA821243B (en) * 1981-03-10 1983-01-26 Novo Industri As Stabilized insulin preparation and method for their production
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK503386D0 (da) * 1986-10-20 1986-10-20 Novo Industri As Peptidpraeparater
JP2606915B2 (ja) 1987-02-25 1997-05-07 ノボ ノルディスク アクティーゼルスカブ 新規インシュリン誘導体
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
AUPO066096A0 (en) 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
JPH10251146A (ja) 1997-03-11 1998-09-22 Toray Ind Inc 糖尿病性神経障害の治療方法
AU1870099A (en) * 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
EP1146896B1 (en) 1999-01-26 2002-07-24 Eli Lilly And Company Monodisperse hexameric acylated insulin analog formulations
RU2300367C2 (ru) 1999-11-15 2007-06-10 Ханамарадди Т. ГАНГАЛ Жидкий лечебный состав для внутривенного введения, содержащий декстрозу и инсулин
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
WO2003094956A1 (en) 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
WO2005009446A1 (en) * 2003-07-17 2005-02-03 Cotherix, Inc. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
EP1696900B1 (en) * 2003-12-16 2010-07-14 United Therapeutics Corporation Use of treprostinil to treat ischemic lesions
ATE433746T1 (de) 2004-03-12 2009-07-15 Biodel Inc Insulinzusammensetzungen mit verbesserter wirkstoffabsorption
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
CA2562614C (en) * 2004-04-12 2013-09-17 United Therapeutics, Inc. Use of treprostinil to treat neuropathic diabetic foot ulcers
WO2006082204A1 (en) * 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
ES2490243T3 (es) * 2005-02-02 2014-09-03 Novo Nordisk A/S Derivados de insulina
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
WO2007038670A2 (en) * 2005-09-30 2007-04-05 Perlegen Sciences, Inc. Methods and compositions for screening and treatment of disorders of blood glucose regulation
DE102006047613A1 (de) * 2006-10-07 2008-04-10 Sanofi-Aventis Deutschland Gmbh Peristaltische Mikropumpe mit wechselbarem Pumpenkopf
DE102006047538A1 (de) * 2006-10-07 2008-04-10 Sanofi-Aventis Deutschland Gmbh Medikamentendosiersystem mittels Mikropumpe
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
EP2545920A1 (en) * 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
EP2328636B1 (en) 2008-08-28 2013-06-12 Medingo Ltd. Device for enhanced subcutaneous insulin absorption
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US20120094902A1 (en) 2009-03-27 2012-04-19 Adocia Fast-acting insulin formulation
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
CA2764423A1 (en) 2009-06-26 2010-12-29 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and an amino acid
BR112012011237A2 (pt) 2009-11-13 2019-09-24 Univ Tokyo agente terapêutico e profilático para diabetes
WO2012006283A1 (en) 2010-07-07 2012-01-12 Biodel Inc. Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of insulin
KR20140030125A (ko) 2010-12-14 2014-03-11 노보 노르디스크 에이/에스 인슐린, 니코틴아미드 및 아미노산을 포함하는 제제
AU2012271361B2 (en) 2011-06-17 2017-03-02 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
JP5912426B2 (ja) * 2011-11-07 2016-04-27 ヤマハ発動機株式会社 リニアコンベア
DK2797622T3 (en) 2011-12-30 2017-01-16 Halozyme Inc PH20 polypeptide variants, formulations and uses thereof
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US20150174209A1 (en) 2012-05-25 2015-06-25 Amylin Pharmaceuticals. Llc Insulin-pramlintide compositions and methods for making and using them
US20150065423A1 (en) * 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
CA2936563A1 (en) 2014-01-13 2015-07-16 Thermalin Diabetes, Llc Rapid action insulin formulations and pharmaceutical delivery systems
US20150273022A1 (en) 2014-02-10 2015-10-01 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations
TWI685348B (zh) * 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
WO2017015760A1 (en) 2015-07-28 2017-02-02 Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et Humaines, S.E.C. A pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول

Also Published As

Publication number Publication date
AR105712A1 (es) 2017-11-01
MY195781A (en) 2023-02-13
DOP2018000059A (es) 2018-04-15
EA201890343A1 (ru) 2018-07-31
MD3340966T2 (ro) 2023-04-30
CR20180118A (es) 2018-03-20
MA42701B1 (fr) 2023-01-31
CL2018000503A1 (es) 2018-08-03
TW201717997A (zh) 2017-06-01
MX2018002482A (es) 2018-06-15
MA42701A (fr) 2018-07-04
ECSP18014922A (es) 2018-04-30
IL256939A (en) 2018-03-29
AU2016310475A1 (en) 2018-02-15
CA2994427C (en) 2019-07-09
US20180140676A1 (en) 2018-05-24
NZ739338A (en) 2019-06-28
TN2018000056A1 (en) 2019-07-08
DK3340966T3 (da) 2022-10-24
EP3340966A1 (en) 2018-07-04
CN107920992A (zh) 2018-04-17
IL256939B (en) 2019-10-31
HRP20221367T1 (hr) 2023-01-06
FI3340966T3 (fi) 2023-01-13
BR112018001755A2 (pt) 2018-09-18
RS63731B1 (sr) 2022-12-30
TWI614025B (zh) 2018-02-11
JP2018507869A (ja) 2018-03-22
AU2016310475B2 (en) 2018-10-18
HUE060626T2 (hu) 2023-03-28
EP3340966B1 (en) 2022-10-12
PH12018500422B1 (en) 2018-08-29
US10925931B2 (en) 2021-02-23
JP6359780B2 (ja) 2018-07-18
ZA201800511B (en) 2019-07-31
JP2018172404A (ja) 2018-11-08
ES2928664T3 (es) 2022-11-21
EA033396B1 (ru) 2019-10-31
PL3340966T3 (pl) 2023-01-30
WO2017034956A1 (en) 2017-03-02
KR20180033276A (ko) 2018-04-02
EP4169505A1 (en) 2023-04-26
PH12018500422A1 (en) 2018-08-29
PE20180782A1 (es) 2018-05-07
SV2018005643A (es) 2018-10-09
US20170056478A1 (en) 2017-03-02
CO2018002026A2 (es) 2018-05-21
CN107920992B (zh) 2021-06-18
UA120142C2 (uk) 2019-10-10
CA2994427A1 (en) 2017-03-02
PT3340966T (pt) 2022-12-05
US20210169988A1 (en) 2021-06-10
US9901623B2 (en) 2018-02-27
KR102018998B1 (ko) 2019-09-05
LT3340966T (lt) 2022-11-25
JP6935364B2 (ja) 2021-09-15

Similar Documents

Publication Publication Date Title
PH12018500422B1 (en) Rapid-acting insulin compositions
PH12016502195A1 (en) Rapid- acting insulin compositions
MX2016008978A (es) Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
SG11201604710XA (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
MX2020002693A (es) Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
PH12017501486A1 (en) Nasal powder formulation for treatment of hypoglycemia
EP3618840C0 (en) STABLE INSULIN FORMULATIONS
MX366499B (es) Composicion farmaceutica liquida.
MX2016017142A (es) Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma.
MX2018009364A (es) Sal de succinato de citisina y uso de la misma.
SA519410672B1 (ar) تركيبات إنسولين سريعة المفعول
PH12018500946A1 (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof